Abstract 101P
Background
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Despite the availability of multiple treatment strategies, the prognosis of the patients with CRC is dismal. The aim of this study is to evaluate the efficacy and safety of cellular immunotherapy (CIT) (the use of autologous natural killer cells, γδTcells and cytokine-induced killer cells) in combination with chemotherapy in patients with CRC.
Methods
A retrospective analysis of 377 patients with colorectal adenocarcinoma from December 2010 to December 2015 was performed, including 97 patients in the CIT+chemotherapy group and 280 patients in the chemotherapy group. The primary endpoints were DFS or PFS (Patients with adjuvant therapy after radical resection of colorectal cancer had the same DFS as PFS). The secondary endpoints were OS, ORR, DCR, adverse reaction rate and treatment tolerance.
Results
The 3-year progression-free survival rate of CIT+chemotherapy group and chemotherapy group was 67.2% vs 53.9% (P < 0.01), and the 5-year OS rate was 74.1% vs 50.8% (P < 0.001). CIT+chemotherapy was independent prognostic factors for both DFS (HR: 0.618, 95% CI: 0.428–0.891) and OS (HR: 0.513, 95% CI: 0.335–0.784). The ORR and DCR of CRC patients with IV staging in the CIT+chemotherapy compared to chemotherapy group were 63.0% vs 50.8% (P = 0.291) and 81.5% vs 65.6% (P = 0.131) respectively. The percentage of CD3+, CD3+ CD4+ cell subsets were significantly increased from 70.11% to 75.87% (P < 0.01), and 42.53% to 44.39% (P = 0.02) in the CIT+chemotherapy group after treatment. Overall adverse reaction rate of CIT+chemotherapy group and chemotherapy group was 75.3% vs 75.4% (P = 0.98) respectively. In patients with stage III, the median chemotherapy course in CIT +chemotherapy compared to chemotherapy group is 8 vs 6 (P = 0.003).
Conclusions
High quality and standardized CIT combined with chemotherapy can promote the survival time, reduce the recurrence rate and improve the immune status of CRC patients. In addition, it is safe and low-toxic which improves the patient's tolerance to chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract